The pharmaceutical industry is bracing for chaos if President Trump follows through on his threat to impose “a major tariff” ...

Hormone receptor (HR)-positive HER2-negative advanced breast cancer is incurable and the aim of treatment is to delay it getting worse and extend how long people live. If the cancer has alterations in ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

This week, the European Commission granted marketing authorization to the expanded use of AbbVie’s ABBV Rinvoq and ...

A "huge breakthrough" in breast cancer treatment has arrived with the NHS approval of a twice-daily pill for the most common form of advanced disease. At such a critical moment in US history, we need ...

Swiss pharma group Novartis has said it will expand its US manufacturing and research and development with a $23bn investment over five years, as drugmakers reconfigure their supply chains as part of ...

A twice-a-day pill for advanced breast cancer has been approved for use on the NHS. The life-extending drug, called ...

Results from a clinical trial showed that capivasertib plus the hormone therapy fulvestrant increased the time before the ...

The Institute of Cancer Research, London, which helped develop the drug, welcomed the move. A twice-a-day pill for the most ...

Listen to this article Mark T. Esser, vice president for vaccines and immune therapies at pharmaceutical giant AstraZeneca, will be the inaugural chief scientific officer and leader of the Paul and ...

Trump said overnight that the US would soon introduce a 'major tariff' on pharmaceuticals to force firms to relocate medicine production to America.